SubHero Banner

Azedra® (iobenguane I 131) – New orphan drug approval

July 30, 2018 - The FDA announced the approval of Progenics Pharmaceuticals’ Azedra (iobenguane I 131) for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy.

Download PDF